Partnership in Implementation Science for Geriatric Mental Health (PRISM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03264378 |
Recruitment Status :
Not yet recruiting
First Posted : August 29, 2017
Last Update Posted : August 30, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Behavioral and Psychological Symptoms of Dementia (BPSD) | Behavioral: Physical Exercise Intervention | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 350 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | The experimental group will receive physical exercise intervention (PEI) that is supported by standardized administrative procedures plus the GTO-ThAI implementation support system designed to improve the quality of implementation of the PEI program. The active comparator group will receive PEI that is supported only by standardized administrative procedures that the Thai government typically uses to promote policy-driven initiatives. |
Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
Masking Description: | None of participants, care providers, or outcome assessor knows whether which participants have been assigned to intervention or control condition. |
Primary Purpose: | Health Services Research |
Official Title: | Partnership in Implementation Science for Geriatric Mental Health (PRISM) |
Estimated Study Start Date : | February 1, 2019 |
Estimated Primary Completion Date : | July 2021 |
Estimated Study Completion Date : | July 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: PEI-GTO-ThAI
Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
|
Behavioral: Physical Exercise Intervention
The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness. |
Active Comparator: PEI-Standard
Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
|
Behavioral: Physical Exercise Intervention
The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness. |
- Implementation outcome score [ Time Frame: Up to 12 months ]Adapted from the Quality Implementation Tool (Meyer et al., 2012), using a total score based on average of ratings, by site implementation team leaders, on a 7-point Likert scale over 48 items across eight dimensions of implementation (e.g. adoption, fidelity, dosage, program reach, differentiation, quality of implementation, implementation cost, sustainability).
- Behavioral and psychological symptoms of dementia (BPSD) [ Time Frame: Up to 12 months ]BPSD will be assessed by the Neuropsychiatric Inventory (NPI), using the total score obtained by summing all the individual domain total scores; each domain score is the product of the frequency score multiplied by the severity score for that behavioral domain.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- (a) adults who are aged 55 and older,
- (b) screen positive for dementia,
- (c) screen positive for BPSD, and
- (d) having a caregiver who is willing to participate in the study.
Exclusion Criteria:
- (a) caregivers who are cognitively not intact, and/or
- (b) not willing to participate in the intervention.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03264378
Contact: Komatra Chuengsatiansup, MD | +66814411401 | loxlix@gmail.com |
Principal Investigator: | Hongtu Chen, PhD | Brigham and Women's Hospital |
Responsible Party: | Hongtu Chen, Assistant Professor, Brigham and Women's Hospital |
ClinicalTrials.gov Identifier: | NCT03264378 |
Other Study ID Numbers: |
2017P000186/PHS |
First Posted: | August 29, 2017 Key Record Dates |
Last Update Posted: | August 30, 2017 |
Last Verified: | August 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | We don't have a plan to share individual participant data. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Dementia Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Neurocognitive Disorders Mental Disorders |